ENZON PHARMACEUTICALS AMENDS TENDER OFFER STATEMENT
| Field | Detail |
|---|---|
| Company | Sc To-I/A - Enzon Pharmaceuticals, Inc. (0000727510) (Subject) |
| Filed Date | Mar 24, 2026 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01, $7.83 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: tender-offer, share-repurchase, amendment
TL;DR
**ENZON PHARMACEUTICALS just updated its tender offer, meaning they're still buying back shares.**
AI Summary
ENZON PHARMACEUTICALS, INC. (CIK: 0000727510) filed an amended Tender Offer Statement by Issuer (SC TO-I/A) on March 24, 2026. This filing, with accession number 0001104659-26-033627, indicates an update to a previous tender offer where the company itself is buying back its own shares. For shareholders, this matters because a tender offer can impact the stock's liquidity and price, potentially offering an opportunity to sell shares back to the company.
Why It Matters
This filing signals an ongoing tender offer by ENZON PHARMACEUTICALS, which could affect the stock's supply and demand dynamics, potentially influencing its market price.
Risk Assessment
Risk Level: medium — While a tender offer can provide liquidity, the terms and ultimate impact on share price are not detailed in this specific filing, introducing some uncertainty.
Analyst Insight
An investor should look for the original tender offer filing (SC TO-I) and any subsequent amendments to understand the specific terms, price, and duration of ENZON PHARMACEUTICALS' share repurchase program before making any decisions.
Key Numbers
- 0000727510 — CIK (Unique identifier for ENZON PHARMACEUTICALS, INC.)
- 2026-03-24 — Filing Date (Date the SC TO-I/A amendment was filed and accepted)
- SC TO-I/A — Form Type (Indicates an amended Tender offer statement by Issuer)
Key Players & Entities
- ENZON PHARMACEUTICALS, INC. (company) — the issuer and subject of the tender offer
- 0000727510 (company) — CIK of ENZON PHARMACEUTICALS, INC.
- 0001104659-26-033627 (dollar_amount) — SEC Accession No. for this filing
- 2026-03-24 (dollar_amount) — Filing Date and Accepted Date
FAQ
What type of filing is this and what does it mean?
This is an SC TO-I/A filing, which stands for 'Tender offer statement by Issuer: [Amend]'. It means ENZON PHARMACEUTICALS, INC. has filed an amendment to a previous statement where the company itself is offering to buy back its own shares from shareholders.
When was this specific amendment filed?
This amendment (Accession No. 0001104659-26-033627) was filed and accepted on March 24, 2026.
Filing Stats: 843 words · 3 min read · ~3 pages · Grade level 11.9 · Accepted 2026-03-24 08:35:53
Key Financial Figures
- $0.01 — Convertible Redeemable Preferred Stock, $0.01 par value per share (the “Series
- $7.83 — ries C Preferred Stock, divided by (ii) $7.83 after giving effect to the Reverse Stoc
Filing Documents
- tm267492d18_sctoia.htm (SC TO-I/A) — 18KB
- 0001104659-26-033627.txt ( ) — 20KB
of the Schedule TO is hereby amended and supplemented by adding
Item 12 of the Schedule TO is hereby amended and supplemented by adding the following exhibits thereto: Exhibit Number Exhibit (a)(1)(K) Press Release issued by Enzon Pharmaceuticals, Inc., dated March 24, 2026 (incorporated by reference to Exhibit 99.1 to the Form 8-K filed by Enzon Pharmaceuticals, Inc. with the SEC on March 24, 2026). 3 SIGNATURE After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. ENZON PHARMACEUTICALS, INC. By: /s/ Richard L. Feinstein Name: Richard L. Feinstein Title: Chief Executive Officer, Chief Financial Officer and Secretary Dated: March 24, 2026 4